{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010489","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.791582+00:00","generated_at":"2026-06-11T19:17:39.456482+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata reports Q2 2023 cash $8.4M; FDA agrees Phase 3 design for DMT310 acne","bullets":["Cash $8.4M at June 30, 2023 vs $6.2M at Dec 31, 2022; net $5.7M from two 2023 financings.","FDA agreed Phase 3 program acceptable for NDA; co-primary endpoints acceptable.","Phase 3 STAR-1 study for DMT310 acne expected to start enrollment in 2H 2023.","R&D expenses $0.8M Q2 2023 vs $1.6M Q2 2022; G&A $0.9M vs $1.1M.","Cash resources expected to fund operations into Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010489","json":"https://secwatch.observer/filing/0001654954-23-010489.json","markdown":"https://secwatch.observer/filing/0001654954-23-010489.md","text":"https://secwatch.observer/filing/0001654954-23-010489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/0001654954-23-010489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:17:39.456482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"103819f0f37747f435b6e1c636a3c1f1a81f681d","claim":"Dermata Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.4 million in cash and cash equivalents.","evidence_excerpt":"to pursue partnership discussions for its DMT410 program for the topical delivery of botulinum toxin. Second Quarter 2023 Financial Results As of June 30, 2023, Dermata had $8.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equivalents resulted from $5.7 million net proceeds from the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/0001654954-23-010489-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$8.4 million in cash and cash equivalents"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}